Evidence map›Paper›PMID 42230576›Full record

ArticleNature communications2026

Recombinant Bombali ebolavirus in cynomolgus macaques as a survival model of Ebola virus disease.

Jacquelyn Turcinovic, Karla A Fenton, Krystle N Agans, Viktoriya Borisevich, Daniel J Deer, Joan B Geisbert, Rachel O'Toole, Dafna Abelson, Natalie S Dobias, Abhishek N Prasad and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jacquelyn TurcinovicGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.ORCID http://orcid.org/0000-0002-7669-223X
Karla A FentonGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Krystle N AgansGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.ORCID http://orcid.org/0000-0002-7319-6935
Viktoriya BorisevichGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Daniel J DeerGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Joan B GeisbertGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Rachel O'TooleGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Dafna AbelsonMAPP Bio, San Diego, CA, USA.ORCID http://orcid.org/0000-0003-4627-6902
Natalie S DobiasGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Abhishek N PrasadGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.ORCID http://orcid.org/0000-0002-4147-2077
Courtney WoolseyGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.ORCID http://orcid.org/0000-0003-3389-0137
John H ConnorDepartment of Virology, Immunology, and Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
César G AlbariñoViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Thomas W GeisbertGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA. twgeisbe@utmb.edu.ORCID http://orcid.org/0000-0003-0858-1877
Robert W CrossGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA. rwcross@utmb.edu.ORCID http://orcid.org/0000-0001-7718-1522

Funding

Regulatory Compliance Core - Galveston National Laboratory BSL4 OperationsUC7AI094660 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Thomas Gary Ksiazek · 2011 to 2026
$208.8M
Research Project 3: siRNA Therapy and Small Molecule Combination Treatment for FilovirusesU19AI142785 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GEISBERT, THOMAS WILLIAM · 2019 to 2023
$35.5M
UTMB Women's Health Research Scholars ProgramK12AR084228 · NIAMS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI ABBEY B BERENSON · 2023 to 2026
$2.7M
NIAID NIH HHS U19 AI142785NIAID NIH HHS UC7 AI094660NIAMS NIH HHS K12 AR084228
6 · The paper itself

Abstract

Ebolaviruses are known to cause severe hemorrhagic fever in humans. A new ebolavirus species, Bombali orthoebolavirus (BOMV), was recently detected in bats from Sierra Leone, Kenya, Guinea, Mozambique, and Tanzania. No infectious BOMV has been isolated from field samples, but an infectious recombinant BOMV clone (rBOMV) was recently established. To estimate disease potential in humans, we challenged cynomolgus macaques with rBOMV. Macaques exhibit hallmark features of Ebola virus disease, including vascular leak, lymphopenia, neutrophilia, and elevated inflammation markers. Consistent with these hallmarks, we detected rBOMV in multiple target tissues at peak viremia, including the liver, lymph nodes, and adrenal gland. All animals survive challenge and develop robust adaptive immune responses, including strong BOMV-specific IgG and neutralizing antibody titers. These data suggest that BOMV may have an attenuated disease phenotype compared to more pathogenic ebolaviruses such as Ebola, Bundibugyo, Sudan, or Taï Forest and may serve as an important model of resolving Ebola Virus Disease.

Indexed as

EbolavirusHemorrhagic Fever, EbolaAdaptive ImmunityAnimalsAntibodies, NeutralizingAntibodies, ViralDisease Models, AnimalFemaleHumansImmunoglobulin GMacaca fascicularisMaleAntibodies, NeutralizingAntibodies, ViralImmunoglobulin G

Identifiers

PMID42230576
PMCPMC13392047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.